一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

APP抗體,Mouse Monoclonal APP Antibody
  • APP抗體,Mouse Monoclonal APP Antibody
  • APP抗體,Mouse Monoclonal APP Antibody
  • APP抗體,Mouse Monoclonal APP Antibody

APP抗體

價格 詢價
包裝 20μl 50μl 100μl
最小起訂量 1μl
發(fā)貨地 湖北
更新日期 2025-05-10
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:APP抗體英文名稱:Mouse Monoclonal APP Antibody
品牌: 艾普蒂產(chǎn)地: 武漢
保存條件: Stored at -20°C for 672 year. Avoid repeated freeze / thaw cycles.產(chǎn)品類別: 抗體
重組: 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat 宿主: Mouse
偶聯(lián)物: 靶點: APP
2025-05-10 APP抗體 Mouse Monoclonal APP Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武漢 Stored at -20°C for 672 year. Avoid repeated freeze / thaw cycles. 抗體

驗證與應(yīng)用

應(yīng)用及物種
WB咨詢技術(shù) Human,Mouse,Rat
IF咨詢技術(shù) Human,Mouse,Rat
IHC咨詢技術(shù) Human,Mouse,Rat
ICC1/200 - 1/1000 Human,Mouse,Rat
FCM咨詢技術(shù) Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

產(chǎn)品詳情

AliasesAAA; AD1; PN2; ABPP; APPI; CVAP; ABETA; PN-II; CTFgamma
Entrez GeneID351
clone3F12F6
WB Predicted band size87kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human APP (AA: 483-699) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

  •  

     

       Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    


  •  

     

       Immunofluorescence analysis of A431 cells using APP mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    


           

參考文獻

以下是關(guān)于APP抗體的3篇代表性文獻摘要簡述:

---

1. **文獻名稱**:Amyloid-β Immunotherapy for Alzheimer’s Disease

**作者**:Schenk, D., et al.

**摘要**:探討抗Aβ抗體通過激活小膠質(zhì)細胞清除腦內(nèi)淀粉樣斑塊的機制,動物實驗顯示免疫療法可減少轉(zhuǎn)基因小鼠的病理沉積,為阿爾茨海默病治療提供新方向。

---

2. **文獻名稱**:Targeting Amyloid-β Oligomers by Passive Immunization

**作者**:Sharman, M.J., et al.

**摘要**:研究發(fā)現(xiàn)針對APP不同表位的單克隆抗體(如6E10、4G8)對Aβ寡聚體清除效果差異顯著,部分抗體可改善模型動物認知功能,提示表位特異性影響治療效果。

---

3. **文獻名稱**:Passive Immunotherapy Against Aβ in APP Transgenic Mice

**作者**:Lemere, C.A., et al.

**摘要**:通過向APP/PS1轉(zhuǎn)基因小鼠注射抗APP抗體,發(fā)現(xiàn)其能穿透血腦屏障并減少可溶性Aβ40/42水平,延緩神經(jīng)突觸損傷,支持被動免疫治療的臨床潛力。

---

如需具體文獻年份或補充其他研究(如臨床抗體藥物aducanumab相關(guān)論文),可進一步調(diào)整。

       

背景信息

APP (amyloid precursor protein) is a transmembrane glycoprotein highly expressed in the brain and involved in synaptic formation, neuronal plasticity, and intracellular signaling. Its proteolytic processing through amyloidogenic or non-amyloidogenic pathways plays a central role in Alzheimer’s disease (AD) pathogenesis. In the amyloidogenic pathway, sequential cleavage by β-secretase (BACE1) and γ-secretase generates neurotoxic amyloid-beta (Aβ) peptides, which aggregate into plaques—a hallmark of AD. APP-targeting antibodies have emerged as critical tools for both research and therapeutic exploration.

Research-grade APP antibodies are widely used to detect APP expression, localization, and processing in cellular and animal models (e.g., transgenic mice), as well as in human biofluids like cerebrospinal fluid (CSF). These antibodies often target specific APP epitopes (e.g., N-terminal, C-terminal, or Aβ domains) to distinguish full-length APP from its proteolytic fragments (e.g., sAPPα, sAPPβ, Aβ). Therapeutically, anti-Aβ antibodies (e.g., aducanumab, lecanemab) aim to clear Aβ plaques or neutralize soluble Aβ oligomers, with some achieving clinical approval despite ongoing debates over efficacy and safety. Other strategies include BACE1 inhibitors or antibodies targeting APP cleavage sites to modulate Aβ production. Challenges remain in optimizing blood-brain barrier penetration, minimizing off-target effects, and addressing the complex pathophysiology of AD beyond Aβ-centric approaches. APP antibodies thus represent a dual-purpose innovation, bridging mechanistic studies and therapeutic development in neurodegenerative research.

       
關(guān)鍵字: APP抗體;APP;APP Antibody;

公司簡介

湖北瑞和寧生物科技有限公司研究創(chuàng)新能力, 擁有完整、科學(xué)、質(zhì)量管理體系。并不斷致力于技術(shù)創(chuàng)新,產(chǎn)品創(chuàng)新和管理創(chuàng)新,贏得了國內(nèi)外廣大用戶的信任。
成立日期 2024-06-24 (3年) 注冊資本 50萬(元)
員工人數(shù) 1-10人 年營業(yè)額 ¥ 100萬以內(nèi)
主營行業(yè) 中間體,化學(xué)試劑 經(jīng)營模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • 湖北瑞和寧生物科技有限公司
普通會員
  • 公司成立:3年
  • 注冊資本:50萬(元)
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營產(chǎn)品:中間體。試劑
  • 公司地址:江漢區(qū)
詢盤

店內(nèi)推薦

APP抗體相關(guān)廠家報價

產(chǎn)品名稱 價格   公司名稱 報價日期
¥265
上海鈺博生物科技有限公司
2026-07-28
¥5301.45
北京孚博生物科技有限公司
2026-07-28
¥948
妙通(上海)生物科技有限公司
2026-07-28
詢價
上海妍琦生物科技有限公司
2026-07-28
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實性、準確性和合法性由發(fā)布商家負責(zé)。 商家發(fā)布價格指該商品的參考價格,并非原價,該價格可能隨著市場變化,或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價格,請咨詢商家,以實際成交價格為準。請意識到互聯(lián)網(wǎng)交易中的風(fēng)險是客觀存在的
主頁 | 企業(yè)會員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號  京公海網(wǎng)安備110108000080號  All rights reserved.
城市| 新密市| 哈密市| 镶黄旗| 墨竹工卡县| 南部县| 朝阳县| 枣强县| 石柱| 泗洪县| 伊春市| 克什克腾旗| 阿巴嘎旗| 河津市| 白水县| 江达县| 施甸县| 合阳县| 邹平县| 松阳县| 成安县| 西安市| 浮梁县| 石泉县| 望奎县| 岳池县| 张北县| 兰溪市| 名山县| 台南市| 丘北县| 休宁县| 鹤庆县| 阳曲县| 洛宁县| 柏乡县| 龙南县| 沂源县| 保靖县| 贵南县| 鄄城县|